InterCure Stock Eyes Breakout as Trump Signals Cannabis Rescheduling, Expanding Flowery Partnership

InterCure Ltd. (NASDAQ: $INCR ( ▲ 5.13% ) ), Israel's leading cannabis company, appears strategically positioned to capitalize on potential U.S. cannabis rescheduling after President Donald Trump shared a video Sunday advocating for Medicare coverage of CBD for seniors. This latest move follows Trump's August announcement that his administration was reviewing rescheduling marijuana from Schedule I to Schedule III, triggering a rally across cannabis stocks.

The timing could prove particularly advantageous for InterCure, which recently announced a strategic acquisition of ISHI (Botanico Ltd.), securing exclusive partnerships with premium American cannabis brands including The Flowery, a leading vertically integrated medical cannabis company with operations in Florida and New York.

"This acquisition represents a significant milestone in our global expansion strategy," said Alexander Rabinovich, CEO of InterCure. "By acquiring ISHI, we gain immediate access to some of America's most sought-after cannabis genetics and proven operational technologies at exactly the moment when we are encouraged by the reported recent momentum in the U.S. around potential cannabis rescheduling."

InterCure's acquisition of ISHI provides immediate access to The Flowery's premium genetics and advanced cultivation methodologies. The Flowery operates state-of-the-art GMP manufacturing facilities in Florida alongside the largest delivery system in Florida's medical market and the largest retail chain in New York state, with plans for continued expansion.

"At The Flowery, our mission is to deliver the highest expressions of Cannabis quality while creating cultural experiences that reflect and elevate the community that built us," said Elad Kohen, Founder and CEO of The Flowery. "Today's announcement strengthens that partnership with greater access and resources, empowering us to expand into new markets the right way."

The potential rescheduling of cannabis would remove significant barriers for cannabis companies, eliminating the punitive 280E tax burden that prevents businesses from claiming standard deductions, enabling access to banking services, and opening doors for institutional investment. For InterCure, which has maintained profitability for 16+ consecutive quarters, these regulatory changes could substantially enhance its already proven business model.

Sara Carter, Trump's nominee for White House Director of Drug Control Policy, recently called cannabis rescheduling a "bipartisan issue" during her confirmation hearing, indicating the administration is "exploring all options" while evaluating research and data.

InterCure's pharmaceutical approach may provide advantages as regulatory barriers potentially fall. Unlike many U.S. operators struggling with profitability, the company has built GMP-certified facilities producing pharmaceutical-grade products that already meet international standards. InterCure maintains a strong balance sheet despite challenges from the October 7, 2023 attacks that damaged its main facility in Israel.

With Trump's apparent warming toward cannabis reform and InterCure's strategic positioning through the ISHI acquisition, investors may find the company's current $81 million market cap represents a potential opportunity ahead of what could be historic regulatory changes in the U.S. cannabis market.

Recent News Highlights

InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands

Cannabis stocks surge after Trump endorses cannabidiol for senior healthcare

Trump, Cannabis Re- Or De-Scheduling And What Comes After

<sub>Legal Disclaimers, Terms & Disclosures: 

By using AlphaCatalyst, any related brands thereof, and any affiliated or partner websites operated under the Wall Street Wire Network (collectively referred to as “Services”), you acknowledge that any and all Services provided are for informational and entertainment purposes only and do not constitute a recommendation for any particular stock, company, investment, commodity, security, transaction, or any other method of trading featured anywhere on AlphaCatalyst or affiliated platforms. AlphaCatalyst does not guarantee the accuracy, completeness, or timeliness of the information or Services provided. Views and opinions presented through the Services, whether expressed by contributors, columnists, external partners, or employees, are not specifically endorsed by AlphaCatalyst or the Wall Street Wire Network, and neither entity accepts responsibility or liability for any actions, financial or otherwise, taken directly or indirectly as a result of engaging with any of the Services offered.</sub>

_{AlphaCatalyst, its employees, operator, partners, affiliates, and any other representatives will not, either directly or indirectly, be held liable, accountable, or responsible in any capacity to you or to any third party for any errors, inaccuracies, or omissions from the Services, including but not limited to market quotes, rumors, unverified chatter, financial data, and news reports; for any interruptions, delays, or transmission errors affecting the availability or accuracy of the Services; or for any damages or losses arising from or related to the use of, reliance on, or inability to access the Services. Some content published by AlphaCatalyst may reference market rumors, speculative chatter, or unconfirmed reports. Readers should be aware that while such unofficial information may be associated with market volatility, price movements based on speculative or incomplete data are subject to change rapidly upon further clarification or the release of official news or filings.}

_{AlphaCatalyst reserves the right at any time to modify any part of its Terms of Service or any portion of the Services, including but not limited to the removal or addition of content, features, contributors, or affiliated content providers, or the introduction of any associated fees or usage conditions. Such changes will take effect immediately upon their publication across the Services and will apply to all users from the time of posting. Please note that trading in foreign currencies, stocks, options, and other securities involves substantial risk and may result in significant financial losses. Neither AlphaCatalyst nor its staff recommends that you buy, sell, or hold any security, and no part of the Services constitutes personalized investment advice. All information provided through the Services is general commentary intended for informational and entertainment use only. AlphaCatalyst disclaims any liability for loss or damage, including without limitation any loss of capital, profit, or opportunity, that may arise directly or indirectly from use of or reliance on the information contained within the Services. We encourage all users to conduct their own due diligence and consult with a certified financial advisor or licensed professional before making any financial decisions.}

_{Content produced by or for AlphaCatalyst may not be reproduced, republished in full, or redistributed in any form without prior written permission from AlphaCatalyst or the Wall Street Wire Network, as applicable.}

_{This content is a form of paid promotional content and advertising. Wall Street Wire receives cash compensation from InterCure Ltd for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire and full disclaimers this article is subject to are available wallstwire.ai/disclosures and we recommend reading them in full.}

_{We are not responsible for any price targets or market size figures that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets or figures may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. This article was not reviewed or approved by the issuer prior to publication and should not be considered an official communication by the issuer.}